Pancreatic Neoplasms  >>  oxaliplatin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00003427: Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

Completed
1
36
US
irinotecan hydrochloride, oxaliplatin
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
04/02
04/02
NCT00266097: Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

Checkmark Data
May 2012 - May 2012: Data
Completed
1
23
US
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, radiation therapy, Oxaliplatin
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
03/09
09/11
NCT00220649: Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas

Completed
1
25
US
gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
St. Luke's-Roosevelt Hospital Center, Sanofi
Pancreatic Neoplasms
 
 
RPGOG1, NCT01048320: Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

Completed
1
36
Europe
Gemcitabine, Oxaliplatin, Imatinib
Royal Marsden NHS Foundation Trust
Advanced Pancreatic Cancer
12/10
12/10
NCT01383538: FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Checkmark FOLFIRINOX combo saridegib
Jun 2012 - Jun 2012: FOLFIRINOX combo saridegib
Completed
1
15
US
FOLFIRINOX, IPI-926, Oxaliplatin, Leucovorin, Irinotecan, 5-FU
Andrew Ko, Infinity Pharmaceuticals, Inc.
Pancreatic Cancer, Adenocarcinoma, Pancreatic Neoplasms
12/12
05/15
NCT00987766: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Completed
1
28
US
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, laboratory biomarker analysis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer, Periampullary Adenocarcinoma, Small Intestine Cancer
07/13
10/16
NCT01233505: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Terminated
1
16
US
veliparib, ABT-888, capecitabine, CAPE, Ro 09-1978/000, Xeloda, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
10/13
 
NCT01413022: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Completed
1
44
US
Oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, Irinotecan, Campto, Camptosar, CPT-11, U-101440E, Leucovorin, CF, CFR, LV, Fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis, flow cytometry, immunohistochemistry staining method, immunohistochemistry, pharmacological study, pharmacological studies, PF-04136309, PF-4136309
Washington University School of Medicine, National Cancer Institute (NCI)
Pancreatic Neoplasms
10/13
09/16
NCT01821612: Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer

Completed
1
23
US
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
09/14
06/18
NCT01446458: Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

Completed
1
13
US
Modified FOLFIRINOX, modifiedFOLFIRINOX, Stereotactic Body Radiotherapy (SBRT), SBRT
Emory University
Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
03/15
03/15
NCT01571024: BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer

Completed
1
17
US
BKM120, buparlisib, mFOLFOX6, Folinic acid (leucovorin), Fluorouracil (5-FU), Oxaliplatin (Eloxatin)
UNC Lineberger Comprehensive Cancer Center
Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
05/15
03/16
NCT01764477: Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Completed
1
20
US
PRI-724
Prism Pharma Co., Ltd., inVentiv Health Clinical
Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
10/15
10/15

Download Options